Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v31i1.4244

NAVIGATING THE VASCULAR FRONTIER: EXPLORING QUERCETIN-BASED DRUG DELIVERY STRATEGIES IN CARDIOVASCULAR THERAPY

Hafiz Muhammad Usman Abid[1*], Muhammad Azeem[2], Muhammad Qaiser[3], Maria Tabassum Faqeer[4], Sobia Abid[5], Muhammad Shakil[6], Aisha Khadija[7], Sana Ronaq[8], Bilal Ahmad Ghalloo[9], Umair Khurshid[10], Khalid Mahmood[11*], Muhammad Hanif[12*]

[1*,2,3,6,8,12*]Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University Multan, Pakistan
[2]Faculty of Pharmacy, Hamdard university Islamabad campus, Pakistan
[5]Department of Zoology, Rahim Yar Khan campus, The Islamia University of Bahawalpur
[6]Accident and Emergency Department Government, Nishtar Hospital Multan, Punjab, Pakistan
[9,10]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, Pakistan
[4]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bahauddin Zakariya University Multan, Pakistan
[7]University College of Pharmacy, University of the Punjab, Lahore, Pakistan
[3,4,7]Drug Testing Laboratory, Punjab, Multan, Pakistan
[11*]Institute of Chemical Sciences, Bahauddin Zakariya University Multan, Pakistan
[1*,9]College of Pharmacy, Tahseen Ahmad Cheema Institute, Bahawalpur 63100, Punjab, Pakistan

***Corresponding Author:** Muhammad Hanif, Khalid Mahmood, Hafiz Muhammad Usman Abid
*Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University Multan, Pakistan. Email: muhammad.hanif@bzu.edu.pk
*Institute of Chemical Sciences, Bahauddin Zakariya University Multan, Pakistan. Email: khalidmahmood@bzu.edu.pk
*College of Pharmacy, Tahseen Ahmad Cheema Institute, Bahawalpur 63100, Punjab, Pakistan Email: usmanabid394@gmail.com

Abstract:
This comprehensive review delves into the utilization of quercetin-based drug delivery systems in cardiovascular therapy, with a primary focus on various nanoparticle strategies, including lipid-based, polymer-based, and other nanocarriers. The investigation aims to assess the potential of these systems in enhancing quercetin's bioavailability, stability, and overall efficacy. Key findings highlight the effectiveness of nanoparticles in targeted delivery to cardiovascular sites and their role in controlled release mechanisms.

Lipid-based nanoparticles play a pivotal role in addressing quercetin's solubility challenges, while their polymer-based counterparts offer adaptability and controlled release capabilities. The exploration extends to alternative nanocarriers such as silica-based and metal-based systems, as well as hybrid nanocarrier approaches. The review discusses various structures like micelles, vesicles, hydrogels, and scaffolds, each contributing to specialized roles in improving quercetin delivery. The strategic use of targeted ligand conjugation emerges as a method to enhance specificity in cardiovascular treatment.

Insights from preclinical animal studies shed light on the effectiveness and safety of quercetin delivery systems, providing a foundation for potential clinical applications. The examination of human trials emphasizes study design elements and outcomes. The review elucidates the mechanisms of quercetin in cardiovascular therapy, encompassing antioxidant, anti-inflammatory, and vasodilatory effects.
Identified challenges, including limitations in bioavailability and safety concerns, set the stage for future collaborative approaches. The review proposes multidisciplinary cooperation and patient-centered strategies to address challenges and expedite clinical translation. Future trends and innovations, such as nanotechnologies, personalized medicine, artificial intelligence, and biomimetic delivery systems, are explored, indicating a promising trajectory for precision in cardiovascular therapy.
In conclusion, optimizing quercetin's therapeutic potential, overcoming delivery challenges, and fostering collaborative strategies emerge as essential implications for advancing cardiovascular therapy.

Graphical abstract:



Figure 1:*Graphical Abstract*

Keywords: Quercetin**,** Drug delivery systems**,** Nanoparticles**,** Cardiovascular therapy**,** Lipid-based nanoparticles**,** Polymer-based nanoparticles**,** Targeted ligand conjugation

1. Introduction

The substantial global health burden that cardiovascular diseases (CVDs) continue to pose has prompted ongoing research into novel therapeutic approaches. The natural polyphenol quercetin has received a lot of attention lately due to its potential applications in cardiovascular therapy. Quercetin, a plant-based compound, has been shown to possess a number of pharmacological characteristics, such as anti-inflammatory, antioxidant, and vasodilatory effects [1]. These attributes make it a viable option for cardiovascular health interventions. A growing corpus of studies and reviews provides support for the idea of looking into quercetin's potential usage in cardiovascular therapy. These studies provide strong evidence for quercetin's potential as a therapeutic agent by highlighting its ability to affect important molecular pathways related to cardiovascular health. Especially, studies on oxidative stress, endothelial function, and lipid metabolism have been conducted in great detail, which has helped to provide a more complex understanding of quercetin's mechanisms of action. The bioavailability and targeted delivery of quercetin to particular vascular sites pose challenges for its

clinical integration, despite its promising attributes. Novel approaches to drug delivery are examined in recent studies with the goal of enhancing quercetin's effectiveness in cardiovascular settings. Targeted ligand conjugation, micelles, and nanoparticle-based carriers stand out as important research topics that may help resolve issues related to quercetin's pharmacokinetics. This introduction, which summarizes key findings from recent studies and review articles, provides the groundwork for a comprehensive examination of quercetin-based drug delivery methods and attempts to navigate the complex terrain of vascular interventions by combining a variety of findings.

A thorough analysis of research articles supporting quercetin's various pharmacological characteristics, which make it a viable option for cardiovascular health interventions, provides support for the investigation of quercetin's potential use in cardiovascular therapy. Studies by M Luo et al. have repeatedly highlighted the strong antioxidant properties of quercetin. Its ability to effectively scavenge reactive oxygen species (ROS) points to a critical role in reducing oxidative stress, which is a major contributor to the development of cardiovascular diseases. Interestingly, quercetin may protect vascular endothelial cells from free radical damage[2].

Quercetin appears as a potential mitigator of chronic inflammation by modulating inflammatory pathways, which is a significant contributor to conditions like atherosclerosis. These findings highlight the potential utility of quercetin as a therapeutic agent for the treatment of cardiovascular diseases associated with inflammatory processes [3]. Quercetin has been shown in studies by Edwards et al. and Egert et al. to improve endothelial function, which can lead to vasodilation and possibly help regulate blood pressure [4]. The justification for quercetin's potential use in cardiovascular therapy is further strengthened by its vasodilatory characteristics. According to research, as demonstrated by Q Deng et al., quercetin may have an effect on lipid metabolism, providing a possible treatment option for dyslipidemia, a known risk factor for cardiovascular diseases [5]. Given the limitations of current treatment approaches, research insights (R Khursheed et al., 2020) have prompted an investigation into quercetin's potential to provide novel approaches to improve therapeutic outcomes, given its diverse pharmacological properties. Optimizing the targeted delivery of quercetin to particular vascular sites while addressing issues with bioavailability is the goal, which includes the use of micelles, nanoparticle-based carriers, and targeted ligand conjugation. According to P Papakyriakopoulou, quercetin's role in cardiovascular therapy is supported by preclinical and clinical evidence that is currently available [6]. This offers an in-depth examination of safety, effectiveness, and translational potential and sheds light on the state of quercetin-based interventions today. Essentially, the goal of this review is to provide a thorough guide to the complex terrain of the vascular frontier by utilizing research articles and review literature. Its main goal is to investigate how quercetin-based medication delivery methods might be used to handle the difficulties that come with cardiovascular treatment.

2. Cardiovascular Diseases: An Overview

Contextualizing the investigation of quercetin-based drug delivery strategies in cardiovascular therapy requires an understanding of the prevalence and consequences of cardiovascular diseases (CVDs). A Joshi et al. offer a thorough picture of the prevalence of CVDs worldwide. These studies highlight how common cardiovascular diseases are and how much of a presence they are in a variety of populations [7]. CVDs are a major cause of morbidity and mortality, so finding novel ways to address their widespread effects on public health is imperative. D Vandenberghe et al. highlight the significant financial cost that CVDs impose. These studies investigate the wider economic impact, which includes reduced quality of life and productivity losses, in addition to the direct costs of healthcare [8]. These revelations highlight how urgent it is to put into practice sensible, long-term plans to control and mitigate the financial effects of cardiovascular illnesses. Studies by V Bucciarelli and colleagues explore the significant effects of cardiovascular disorders on people's quality of life. The studies highlight the various difficulties that people with CVDs encounter on a social, emotional, and physical level [9]. This acknowledgement underlines how important it is to investigate cutting-edge treatment

options, such as quercetin-based therapies, in order to address the complexity of cardiovascular therapy. An analysis of current cardiovascular disease (CVD) treatment approaches offers important insights into current therapeutic modalities and emphasizes the need for novel approaches. Research conducted by O Mourad et al. highlight the common use of pharmacological interventions in the treatment of cardiovascular diseases [10]. Important components of the current treatment plan are core medications, such as beta-blockers, antiplatelet agents, and statins. Although beneficial in addressing certain aspects of CVDs, these diseases are complex and often require a comprehensive, multimodal approach.

M Zakir et al. provide insight into the critical role that interventional procedures play in the state of treatment today. Procedures like stent placement and angioplasty offer focused treatments for particular heart conditions. Procedural interventions, however, may come with inherent risks and limitations and may not adequately address the multifactorial aspects of CVDs [11]. G Geremew et al. highlight the significance of lifestyle modifications in cardiovascular therapy. Integrative management includes diet modifications, consistent exercise, and quitting smoking [12]. Although modifying one's lifestyle can greatly lower risk, there are obstacles in the way of patient compliance and long-term sustainability when implementing these changes. Recognizing the difficulties in managing cardiovascular diseases and the urgent need for novel approaches is reliant on an understanding of the limitations present in current therapeutic approaches. Research by S Hogervorst et al. highlights the drawbacks of pharmaceutical interventions. Even though drugs are effective in treating some aspects of CVDs, issues with side effects, patient adherence, and the need for customized treatment plans remain [13]. These drawbacks emphasise the need for innovative therapeutic modalities that provide improved safety profiles and tailored strategies. M Adhami et al. illuminated difficulties related to interventional procedures. Limitations arise in addressing the systemic nature of CVDs, even though targeted solutions are offered by procedures like angioplasty and stent placement [14]. A thorough reevaluation of interventional strategies is required due to concerns regarding restenosis, procedural risks, and the necessity of repeat interventions. Pedretti, et al. highlight difficulties associated with changing one's lifestyle. Notwithstanding the widely recognised advantages of dietary adjustments, physical activity, and quitting smoking, real-world obstacles stand in the way of attaining long-term behavioural changes [15]. Innovative strategies that improve the viability and long-term adherence to lifestyle interventions are needed to overcome these obstacles.

3. Quercetin: A Natural Polyphenol

3.1 Biochemical properties

Biochemical properties are important for understanding its potential in cardiovascular therapy. Important aspects of the biochemical profile of quercetin are covered in this section.

3.1.1 Robust Antioxidant Capacity

Strong antioxidant properties of quercetin, as demonstrated by research by TH Le et al. emphasise the compound's ability to scavenge reactive oxygen species and reduce oxidative stress, which is linked to cardiovascular diseases. Because it neutralizes free radicals, the polyphenolic compound quercetin shows promise in treating oxidative damage in vascular tissues [16, 17].

3.1.2 Anti-Inflammatory Attributes

Studies like those by Boots et al. highlight quercetin's anti-inflammatory properties. Quercetin has the potential to reduce chronic inflammation linked to cardiovascular diseases by altering inflammatory pathways. This anti-inflammatory property increases the importance of quercetin in preserving vascular health [18].

3.1.3 Vasodilatory Effects

According to studies by F Nazari-Khanamiri et al. quercetin's capacity to improve endothelial function is the source of its vasodilatory effects. This contribution to vasodilation is consistent with the goals

of cardiovascular therapy, indicating a potential role for quercetin in blood pressure regulation and general vascular health [19].

3.1.4 Modulation of Lipid Metabolism

Research such as that conducted by M Pytliak et al. adds to our knowledge about the effects of quercetin on lipid metabolism. Quercetin has the ability to alter lipid profiles, which presents opportunities for the treatment of dyslipidemia, a known cardiovascular risk factor. Because of its biochemical adaptability, quercetin is a good option to treat cardiovascular health issues related to fat [20].

3.2 Health Benefits

Examining quercetin's health benefits offers an essential perspective for comprehending its potential in cardiovascular therapy. Based on findings from reviews and research articles, this section explores the various health benefits of quercetin [21].

3.2.1 Safeguarding Cardiovascular Health

Studies by MC Chiang et al. highlight the protective effects of quercetin on cardiovascular health. Its anti-inflammatory and antioxidative qualities help to reduce inflammation and oxidative stress in the cardiovascular system, which may slow the advancement of heart-related illnesses [22].

3.2.2 Enhancement of Endothelial Function

The ability of quercetin to improve endothelial function has been linked to several health benefits, as studies by F Aghababaei et al. have demonstrated. Greater blood vessel dilatation is correlated with improved endothelial function, which promotes improved blood flow and may be advantageous for controlling blood pressure and vascular health [23] .

3.2.3 Broad Anti-Inflammatory Effects

According to Shabir et al. quercetin's anti-inflammatory properties go beyond cardiovascular health. Quercetin may have wider health benefits by modifying inflammatory pathways, which may help manage inflammatory conditions outside of the cardiovascular system [18].

3.2.4 Robust Antioxidant Defense

According to studies by Y Zhou et al. quercetin's strong antioxidant capacity creates a systemic antioxidant defence. This goes beyond cardiovascular health, implying that it may be able to fight oxidative stress in all areas of the body and setting the stage for its potential to support general health [24, 25].

3.3 Role in Cardiovascular Health

To fully realize quercetin's potential in therapeutic interventions, it is imperative to understand its precise role in cardiovascular health. Drawing from research articles and review literature, this section delves into the complex ways that quercetin supports cardiovascular health.

3.3.1 Enhancing Endothelial Function

Research conducted by Yamagata et al. highlights the function of quercetin in improving endothelial function. Quercetin has the potential to improve blood vessel health by promoting vasodilation through enhanced endothelial function. This ability raises the possibility of advantages in blood pressure control and cardiovascular health promotion [26].

3.3.2 Regulation of Blood Pressure

M Aatif et al.'s research highlights quercetin's potential for blood pressure regulation. The compound's antioxidant and anti-inflammatory qualities, along with its vasodilatory effects, support a holistic strategy for preserving ideal blood pressure levels, which are crucial for cardiovascular health [27].

3.3.3 Strengthening Antioxidant Defenses

According to research by Y Zhou et al., quercetin's strong antioxidant potential is essential for cardiovascular health. Quercetin may aid in preventing oxidative damage within the cardiovascular system and thereby promoting heart health by scavenging free radicals and reducing oxidative stress [24].

3.3.4 Modulation of Inflammatory Processes

According to studies by Papakyriakopoulou et al., quercetin's anti-inflammatory properties are crucial for cardiovascular health. Quercetin offers a potential treatment and prevention option for inflammatory conditions within the cardiovascular system by modulating inflammatory pathways, which may reduce chronic inflammation linked to cardiovascular diseases [6, 28].

4. Challenges in Cardiovascular Drug Delivery

Deciphering the complexities of cardiovascular medication delivery exposes a significant obstacle: blood-brain barrier (BBB) penetration. Research by NA Mohamed et al. emphasise how strong the blood-brain barrier (BBB) is. The brain's natural defence mechanism against dangerous substances poses a challenge to drug delivery strategies aimed at addressing cardiovascular issues [29]. The BBB's selective permeability may pose obstacles to quercetin's potential effectiveness in cardiovascular therapy.

R Mehboob insights highlight the need for drug delivery approaches that improve quercetin's BBB crossing capacity. This guarantees that it reaches the cerebral vasculature, where it may affect neurological aspects linked to cardiovascular disorders [30]. It becomes critical to investigate novel approaches for BBB penetration, as covered by HK Alajangi, et al.[31] To help quercetin cross the blood-brain barrier more easily, research into ligand conjugation, nanoparticle-based carriers, and other cutting-edge delivery methods is still underway. These strategies are crucial for resolving the barrier of BBB penetration and maximizing the delivery of drugs based on quercetin for focused therapeutic interventions in cardiovascular diseases that impact the cerebral vasculature. Reaching targeted delivery to vascular tissues is a significant challenge when delving into the complexities of cardiovascular drug delivery. Research by Wanget al. highlight how crucial it is to achieve accuracy in targeted drug delivery to vascular tissues. Because cardiovascular diseases are complex, it is important to take a targeted approach to making sure medication, like quercetin, gets to the right vascular sites quickly and effectively. It is essential to comprehend the difficulties associated with therapeutic agent distribution within the cardiovascular system [32]. Findings from publications like Dewanjee highlight the necessity of creative drug delivery techniques to get around issues with uniform distribution and guarantee that quercetin precisely reaches target regions [33].

It is imperative to investigate nanoparticle-based approaches for targeted drug delivery, as mentioned by G Lohiya et al. By enhancing the specificity of quercetin delivery to vascular tissues through nanoparticles, the problem of non-specific distribution may be mitigated and the overall therapeutic effect may be improved. Examining the difficulties associated with delivering drugs to the cardiovascular system clarifies a major issue: bioavailability [34]. Research conducted by P Papakyriakopoulou et al. highlights the difficulty associated with quercetin's restricted absorption and distribution. Its low water solubility and low bioavailability make it difficult to achieve therapeutic concentrations in cardiovascular tissues. To increase quercetin's overall effectiveness, strategies to get around these restrictions are essential [6]. S Kaur clarifies the difficulties quercetin presents with metabolism and excretion. Quick metabolism and excretion could shorten quercetin's bloodstream half-life, reducing its potential medicinal benefit [35]. Novel approaches to drug delivery are required to address these metabolic and elimination-related issues. It becomes essential to investigate formulation enhancements, as S Kaur et al. have discussed. The goal of novel formulations, such as encapsulation methods and Nano formulations, is to increase quercetin's bioavailability. By improving its solubility, stability, and general absorption, these tactics aim to improve the drug's delivery to cardiovascular tissues [36].

Table 1: Mechanism of action of quercetin in various cardiovascular disorders

Properties	Mechanism of action	Physiological effect	Reference
Robust Antioxidant Capacity	Donation of electrons, Enzyme activation, metal chelation, Quenching of Singlet Oxygen, Regeneration of Other Antioxidants	Cellular Protection, Anti-Inflammatory Effects, Cardiovascular Health, Immune System Support, Neuroprotection, Skin Health, Cancer Prevention	[37]
Anti-Inflammatory Attributes	Inhibition of Pro-Inflammatory Mediators, Inhibition of Inflammatory Enzymes, Reduction of Reactive Oxygen Species (ROS), NF-κB Pathway Modulation, Modulation of Immune Cell Activity, Reduction of Adhesion Molecules	Reduced Inflammation, Pain Relief, Improved Joint Function, Cardiovascular Protection, Neuroprotection, Improved Gut Health, Enhanced Immune Regulation, Reduced Oxidative Stress, Lowered Risk of Chronic Diseases	[38]
Vasodilatory Effects	Nitric Oxide (NO) Release, Prostacyclin (PGI2) Production, Adenosine Release, Potassium Channel Activation, Calcium Channel Blockade, Bradykinin-Induced Vasodilation	Blood Pressure Regulation, Increased Blood Flow to Tissues, Heat Dissipation, Response to Exercise, Endocrine Regulation, Prevention of Ischemia	[6]
Modulation of Lipid Metabolism	Hormonal Regulation, Enzymatic Control, Transcriptional Regulation, Lipolysis, Lipid Transport, Bile Acid Synthesis	Energy Homeostasis, Weight Regulation, Blood Lipid Levels, Cellular Structure and Function, Hormone Synthesis, Insulin Sensitivity	[39]
Enhancement of Endothelial Function	Antioxidant Defense, Anti-Inflammatory Effects, Prostacyclin (PGI2) Synthesis, Endothelial Progenitor Cells (EPCs), Omega-3 Fatty Acids, Phosphodiesterase Inhibition	Improved Vasodilation, Reduced Vasoconstriction, Anti-Thrombotic Effects, Lowered Oxidative Stress, Improved Insulin Sensitivity, Positive Impact on Cardiovascular Risk Factors	[40]
Broad Anti-Inflammatory Effects	Inhibition of Pro-Inflammatory Mediators, Reduction of Inflammatory Mediators, Inhibition of Inflammatory Enzymes, Antioxidant Activity, Resolution of Inflammation,	Reduced Inflammation, Pain Relief, Improved Joint Function, Cardiovascular Protection, Improved Respiratory Function, Gastrointestinal Health, Enhanced Immune Regulation	[5]
Robust Antioxidant Defense	Metal Ion Chelation, Induction of Phase II Detoxification Enzymes, Mitochondrial Protection, Cellular Repair and Renewal	Cellular Protection, DNA Protection, Inflammation Modulation, Skin Health, Eye Health, Detoxification Support, Reduced Risk of Chronic Diseases, Anti-Aging Effects	[41]
Enhancing Endothelial Function	(NO) Production, (EDHF), Shear Stress and Physical Activity, Dietary Factors	Improved Vasodilation, Enhanced Blood Flow, Cardioprotective Effects	[42]
Modulation of Inflammatory Processes	Inhibition of Pro-Inflammatory Cytokines, NF-κB Inhibition, Gut Microbiota Modulation, Epigenetic Modifications	Reduced Tissue Damage, Enhanced Immune Regulation, Prevention of Fibrosis	[4]

5. Quercetin-based Drug Delivery Systems

5.1 Nanoparticles

Investigating quercetin-based drug delivery methods highlights the critical function of nanoparticles. Research conducted by SR Alizadeh et al. highlights the potential of nanoparticles as a tactical approach to tackle quercetin's bioavailability issues. The solubility, stability, and overall absorption of quercetin are all improved by using nanoparticles, which increases its bioavailability [43]. This guarantees that therapeutic concentrations enter cardiovascular tissues efficiently. Studies by Arshad et al. highlight the potential of nanoparticles to enable improved targeting. Quercetin can be precisely delivered to the targeted cardiovascular locations with tailored nanoparticles that are made to target specific vascular sites [44]. The therapeutic effect is maximized and off-target effects are minimized with this targeted approach. Studies by Weisany et al. provide insights that highlight the usefulness of nanoparticles in controlled release mechanisms. With the help of nanoparticles, quercetin can be released gradually and at therapeutic concentrations that are maintained. By extending quercetin's

bloodstream presence through controlled release, its therapeutic potential for cardiovascular interventions is maximized [45].

5.2 Lipid-based Nanoparticles

Regarding quercetin-mediated drug delivery, lipid-based nanoparticles are a noteworthy approach. Research conducted by K Wadhwa and colleagues emphasise the importance of lipid-based nanoparticles in addressing quercetin's solubility issues. Lipid carriers are essential for increasing quercetin's solubility and enabling its efficient integration into the nanoparticle system [46]. This improvement helps to deliver the drug to cardiovascular tissues more effectively and with better bioavailability. Findings from studies by G Hädrich, et al. demonstrate how lipid-based nanoparticles help keep quercetin stable. Because the lipid matrix shields quercetin from breakdown, it is more stable during the delivery process [47]. Maintaining the therapeutic efficacy of quercetin in cardiovascular interventions requires this stability. Results from studies by DP Gaspar, et al. highlight the need to modify lipid-based nanoparticles for specific distribution. Researchers can modify nanoparticles to selectively target particular cardiovascular sites by functionalizing lipid carriers[48]. By reducing off-target effects and optimizing therapeutic outcomes, this targeted approach maximizes quercetin delivery precision [49].

5.3 Polymer-based Nanoparticles

When it comes to quercetin-based drug delivery systems, polymer-based nanoparticles are a useful and adaptable approach. Research by S Nathiya, et al. emphasise the critical role polymer-based nanoparticles play in resolving issues with quercetin stability and solubility. Polymers serve as efficient carriers, increasing quercetin's solubility and preventing its breakdown. This enhancement helps to maintain quercetin's therapeutic efficacy and boost its bioavailability [50]. Research findings by G Hoti et al. highlight the usefulness of polymer-based nanoparticles in mechanisms of controlled release. These nanoparticles offer the capacity to control quercetin release gradually, guaranteeing long-term therapeutic concentrations. Controlled release maximizes quercetin's potential for cardiovascular interventions by prolonging its bloodstream presence [51]. Studies by RS Soumya et al. highlight the importance of tailoring polymer-based nanoparticles for specific delivery. Nanoparticles can be modified to selectively target particular cardiovascular sites by functionalizing polymer carriers. This focused strategy improves quercetin delivery accuracy, reducing side effects and optimizing therapeutic results [52].

5.4 Other Nanocarriers

Diverse alternative nanocarriers in the field of quercetin-based drug delivery systems expand the possibilities for cardiovascular therapy. In this section, we shall examine other nanocarriers besides lipids and polymers and emphasizes how they might improve the delivery of quercetin for cardiovascular interventions.

5.4.1 Utilizing Silica-based Nanocarriers

Studies conducted by Bhattacharya et al. shed light on the use of silica-based nanocarriers in quercetin delivery. Because of their unique qualities such as their large surface area and biocompatibility, silica nanoparticles are seen as strong contenders to increase quercetin solubility and facilitate controlled release, which will ultimately improve therapeutic results [33].

5.4.2 Harnessing Metal-based Nanoparticles

Research by M Rudrapal et al. examine the possibility of using metal-based nanoparticles as quercetin carriers. The distinct physicochemical characteristics of metal nanoparticles, like gold and silver, can be used to target delivery and enhance bioavailability, thereby enhancing quercetin's overall effectiveness in cardiovascular therapy [53].

5.4.3 Developing Hybrid Nanocarrier Systems

S Kaur et al research articles provide insights into the development of hybrid nanocarrier systems for quercetin. These systems combine various nanomaterials, such as metals, polymers, and lipids, to maximize the benefits of each element. The goal of hybrid nanocarrier systems is to increase quercetin's therapeutic effect and delivery efficiency overall [35].

5.5 Micelles and Vesicles

Examining the field of quercetin-based drug delivery systems highlights the unique characteristics of vesicles and micelles as carriers that explores the use of micelles and vesicles as specialized vehicles to improve the delivery, solubility, and therapeutic efficacy of quercetin in cardiovascular therapy. Research conducted by X Qi et al. highlights the significance of micelles in enhancing the solubility of quercetin. Because micelles are made of amphiphilic molecules, quercetin is more soluble in aqueous solutions because of the hydrophobic core that encloses it. This improvement helps to make the substance more bioavailable, which guarantees effective delivery to the tissues of the heart [54]. Research by Papakyriakopoulou et al. provides insights into the use of vesicles, like liposomes, for quercetin delivery. Because vesicles offer controlled release mechanisms, quercetin can be released gradually over time. By prolonging quercetin's bloodstream presence through controlled release, its potential for cardiovascular interventions is maximized [6]. Studies by Rathod demonstrate the potential of vesicles and micelles for targeted delivery. Researchers can modify these carriers to selectively target particular cardiovascular sites by functionalizing them. This focused strategy improves quercetin delivery accuracy, reducing side effects and optimizing therapeutic results [55].

5.6 Hydrogels and Scaffolds

Examining the complex terrain of quercetin-based drug delivery systems reveals the special roles that hydrogels and scaffolds play. In this section we examine how hydrogels and scaffolds function as specialized platforms to improve the delivery, bioavailability, and therapeutic impact of quercetin in cardiovascular therapy by synthesizing insights from research articles and review literature. Studies conducted by CS Lee et al. highlight the function of hydrogels as biocompatible matrices for quercetin delivery. Because of their high-water content, hydrogels function as drug depots, releasing quercetin gradually. By extending the time quercetin is present in the cardiovascular system, this controlled release mechanism improves treatment results [56]. Scaffolds are used to deliver quercetin; research by Dhasmana et al. clarifies this. Scaffolds provide three-dimensional support structures that help quercetin be incorporated and released gradually [57]. This method improves quercetin's overall stability and bioavailability, which makes it a viable tactic for cardiovascular treatment interventions. Studies by Rampin et al. highlight the opportunities that hydrogels and scaffolds present for targeted delivery in tissue engineering applications. By functionalizing these platforms, quercetin delivery can be matched to therapeutic requirements by enabling specific targeting within cardiovascular tissues. By taking a targeted approach, quercetin intervention can be more precisely targeted while minimizing off-target effects [58].

5.7 Targeted Ligand Conjugation

In the wide field of quercetin-based drug delivery, targeted ligand conjugation stands out as a tactical method to attain specificity and accuracy in cardiovascular treatment. This section explores the use of targeted ligand conjugation to improve quercetin delivery, targeting, and therapeutic efficacy by synthesizing knowledge. Research by Kaur, emphasise how important targeted ligand conjugation is to improving the accuracy of quercetin targeting. When particular ligands are attached to quercetin carriers, their affinity for receptors on cardiovascular cells is increased. This results in optimal quercetin delivery to targeted sites with low off-target effects [59]. Findings from studies by Dorostkar et al. shed light on the application of receptor-mediated endocytosis made possible by targeted ligand conjugation. By binding with cell surface receptors through this mechanism, quercetin carriers can start the process of cellular uptake through endocytosis. By ensuring quercetin is efficiently delivered to cardiovascular cells, its therapeutic potential is maximized through such targeted uptake [60].

Studies conducted by S Singh et al. demonstrate the possibility of customized targeting approaches enabled by ligand conjugation. Quercetin delivery to particular cardiovascular subtypes can be optimized through a customized approach, made possible by the customization of ligands based on individual patient profiles. This tailored approach improves quercetin-based interventions' overall efficacy [61].

Table 2: Drug delivery systems for Quercetin

Drug delivery system	Components	Method of preparation	Advantages	Application in CVS disease	References
Nanoparticles	Quercetin, Polymer Matrix, Surfactants, Stabilizers, Targeting Ligands, Solvents	Solvent Evaporation/Emulsion Method, Solvent Diffusion Method, Nanoemulsion Technique, Solid Lipid Nanoparticle (SLN) Method	Improved Bioavailability, Controlled Release, Targeted Delivery, Versatility in Formulation	Endothelial Dysfunction, Hypertension Management, Cholesterol Modulation, Cardioprotective Effects	[62, 63]
Lipid-based Nanoparticles	Lipid Core, Emulsifiers, Stabilizers, Co-Solvents or Co-Surfactants, Antioxidants, Cryoprotectants	Solvent Emulsification-Evaporation Method, Solvent Emulsification-Diffusion Method,	Controlled Release, Targeted Delivery, Protection from First-Pass Metabolism, Versatility in Formulation	Atherosclerosis Management, Endothelial Protection, Antihypertensive Effects, Antioxidant Therapy	[64]
Polymer-based Nanoparticles	Polymer Matrix, Quercetin, Emulsifiers, Crosslinking Agents, pH Adjusting Agents, Chelating Agents	Nanoprecipitation Method,	Stability Enhancement, Targeted Delivery, Combination Therapy, Improved Cellular Uptake, Biocompatibility	Atherosclerosis Management, Myocardial Infarction (Heart Attack) Recovery, Mitigation of Thrombosis Risk, Combination Therapy Possibilities	[65]
Utilizing Silica-based Nanocarriers	Silica Nanoparticles, Silane Coupling Agents, pH Adjusting Agents, Targeting Ligands, Plasticizers	Sol-Gel Method	Controlled Release, Improved Targeting, Ease of Surface Modification, Drug Loading Efficiency	Endothelial Protection, Cholesterol Modulation, Mitigation of Thrombosis Risk, Combination Therapy Possibilities	[66]
Harnessing Metal-based Nanoparticles	Metal Nanoparticles, Surface Coatings, Capping Agents, Surface Functionalization, pH-Responsive Components, Biocompatible Polymer Matrix	Gold Nanoparticle Synthesis	Enhanced Cellular Uptake, Synergistic Effects with Metal Nanoparticles, Theranostic Applications, Protection from Degradation, Multifunctional Nanoparticles	Atherosclerosis Management, (Heart Attack) Recovery, Mitigation of Thrombosis Risk	[67]

Developing Hybrid Nanocarrier Systems	Lipid-Based Nanocarriers, Polymer-Based Nanocarriers, Metal-Based Nanoparticles, Dendrimers, Drug-Loaded Nanoparticles, Surface-Functionalized Nanocarriers, pH-Sensitive Components	Depending on the specific nanocarriers chosen	Multifunctionality, Enhanced Drug Stability, Targeted Drug Delivery, Reduced Toxicity, Theranostic Capabilities, Customizable Drug Release Profiles, Potential for Personalized Medicine	Antihypertensive Effects, Cholesterol Modulation, Mitigation of Thrombosis Risk, Combination Therapy Possibilities	[68]



Figure 2:Drug delivery systems of quercetin for cardiovascular disease

6. Preclinical and Clinical Studies

6.1 Animal Studies

An important step in the evaluation process for quercetin-based drug delivery strategies in cardiovascular therapy is the use of animal studies. This section investigates the effectiveness and safety of different quercetin delivery systems in preclinical settings, drawing on insights from previous literature. Studies conducted in animal models by Papakyriakopoulou et al. highlight the efficacy of quercetin-based drug delivery systems. These investigations offer important information about how various delivery modalities affect molecular targets, impact cardiovascular pathways, and affect the course of disease. Evaluating effectiveness in animal models establishes the foundation for possible clinical translational applications [6]. Understanding the safety profile of quercetin-based drug delivery systems in animal models is made easier by the understanding gained from safety assessments carried out by Mukherjee et al. Analyzing factors like systemic effects, biochemical markers, and organ toxicity yields vital information for evaluating the overall safety of these delivery

methods. Clinical trial and potential human application decisions are influenced by data generated from animal studies [69].

6.2 Human Trials

Human trials are essential for determining the viability and effectiveness of quercetin-based medication delivery strategies as they progress from preclinical evaluations to clinical settings. This section reviews the design, findings, and implications of human trials investigating the use of quercetin in cardiovascular interventions, synthesizing knowledge from research articles and review literature. Studies by Papakyriakopoulou et al. shed light on important elements of the study design in human trials using drug delivery systems based on quercetin. These trials' structure is heavily influenced by factors like delivery methods, dosage schedules, and patient selection criteria. Accurately interpreting the results and implications of human trials requires a thorough understanding of study design [6]. The perspectives provided by Kozłowska et al. on the outcomes and implications of human trials provide a comprehensive understanding of quercetin's efficacy in cardiovascular therapy. For the benefit of both clinicians and researchers, evaluation of parameters like treatment efficacy, safety profiles, and patient outcomes yields useful data. The conclusions derived from these studies have a major impact on how quercetin-based therapies progress in the field of cardiovascular health [70].

7. Mechanisms of Quercetin in Cardiovascular Therapy

Comprehensive research, such as that conducted by Naomi, et al. highlights the antioxidant and anti-inflammatory aspects of quercetin while unravelling the mechanisms by which it benefits cardiovascular therapy. Natural polyphenol quercetin exhibits strong antioxidant properties through its ability to neutralize reactive oxygen species (ROS) and block the pathways that lead to oxidative stress [70]. Studies show that quercetin increases the activity of natural antioxidant enzymes such as catalase and superoxide dismutase (SOD), which reduces oxidative damage in cardiovascular tissues. Research findings demonstrate quercetin's anti-inflammatory properties through its impact on important inflammatory pathways. Quercetin is an effective inhibitor of nuclear factor-kappa B (NF-κB), a transcription factor that plays a central role in inflammation, as well as a regulator of pro-inflammatory cytokine release. This combined effect helps to reduce inflammation, which is a major contributor to the development of cardiovascular illnesses[60].Many studies have examined the complex mechanisms of quercetin in cardiovascular therapy, such as those conducted by Y Zhou et al ,which shed light on this natural polyphenol's vasodilatory effects [71].By affecting the function of the endothelial cells that line blood vessels, quercetin notably demonstrates endothelium-dependent vasodilatory effects. According to recent research, quercetin maintains the production of nitric oxide (NO) and inhibits its breakdown, increasing the bioavailability of this essential vasodilator. This process promotes vasodilation by assisting vascular smooth muscle cells in relaxing [72].

The results of the research highlight the function of quercetin in controlling a number of vasoactive molecules that are essential for controlling vascular tone. While encouraging the release of prostacyclin, a vasodilator, quercetin also affects the activity of the vasoconstrictor endothelin-1. The vasodilatory effects of quercetin are further supported by this dual modulation, which helps to maintain normal vascular function [73].A range of studies, such as those conducted by Papakyriakopoulou et al., have shed light on the intricate mechanisms of quercetin in cardiovascular therapy and its impact on lipid metabolism. Quercetin regulates important lipid profiles in the cardiovascular system, which has a substantial effect on lipid metabolism [6]. Research suggests that quercetin may have an impact on triglycerides, low-density lipoprotein (LDL) cholesterol, and cholesterol levels. By preserving a balanced lipid profile, these regulatory effects help to reduce risk factors linked to cardiovascular illnesses. Research findings show that quercetin regulates lipid peroxidation, a process connected to the onset of atherosclerosis [74]. Quercetin helps to maintain the integrity of cell membranes and stop the development of atherosclerotic plaques by blocking oxidative

damage to lipids. Quercetin's ability to protect lipid structures highlights its potential to improve cardiovascular health [75].

8. Current Challenges and Future Perspectives

8.1 Remaining Hurdles in Quercetin-based Drug Delivery

Research on quercetin-based drug delivery strategies for cardiovascular therapy is still facing several obstacles, according to a thorough review of recent studies, such as those by MB McGuckin et al. The limited bioavailability of quercetin poses challenges despite its promising therapeutic potential. The compound exhibits suboptimal systemic concentrations due to its low aqueous solubility and absorption issues [76]. Unlocking quercetin's full therapeutic potential in cardiovascular interventions requires overcoming these bioavailability limitations. It is still difficult to deliver quercetin precisely to certain vascular locations. Significant obstacles include things like fast clearance, off-target effects, and inadequate accumulation at intended sites. Developing targeted delivery methods is the main goal of ongoing research to overcome these obstacles and improve quercetin's therapeutic effects. For quercetin-based drug delivery systems to successfully translate into clinical practice, safety must be guaranteed. Research brings up questions about possible toxicity and side effects, highlighting the necessity of fully comprehending the dose-response relationship and long-term safety profiles. It is imperative that these safety issues are resolved in order to successfully incorporate quercetin into cardiovascular treatment plans. To fully utilize quercetin in cardiovascular therapy, it is imperative to recognise and overcome these enduring obstacles. To overcome these obstacles and influence the future development of successful quercetin-based interventions, ongoing research projects and creative drug delivery strategies are essential [77].

8.2 Potential Collaborative Approaches

Novel and cooperative approaches are required to overcome the obstacles in quercetin-based medication delivery for cardiovascular therapy, as evidenced by studies conducted recently by T Goswami, et al.[78]. Encouraging multidisciplinary cooperation between bioengineers, cardiovascular researchers, and pharmaceutical scientists can advance an all-encompassing strategy to address issues. Through the integration of specialized knowledge from various domains, scientists can develop all-encompassing approaches to improve quercetin's bioavailability, streamline delivery mechanisms, and efficiently evaluate safety profiles. Partnerships between the academic and pharmaceutical sectors can accelerate the conversion of research discoveries into useful applications. Collaborative efforts expedite the development of novel drug delivery systems and optimize production process scaling, thereby advancing quercetin-based interventions towards clinical application. Incorporating patient perspectives into research endeavours yields significant insights regarding the feasibility and acceptability of therapies based on quercetin. The creation of delivery systems that are in line with patient preferences is guided by patient-centered approaches, which improve treatment outcomes overall and adherence [79].

8.3 Future Trends and Innovations

Future trends and innovations are of interest as long as quercetin-based drug delivery for cardiovascular therapy faces obstacles. Recent research findings, such as those from studies by V Harish et al., shed light on potential directions for field advancement. Using cutting-edge nanotechnologies with tunable nanocarriers appears to be a promising direction. Enhancing quercetin's solubility and stability through innovations in nanoscale drug delivery systems may help with bioavailability issues and allow for targeted delivery to specific locations in the cardiovascular system [80]. Personalized medicine may be part of the trajectory that quercetin-based therapies take in the future [81]. The optimization of treatment outcomes can be achieved by customizing drug delivery systems to individual patient characteristics, genetics, and disease profiles. This guarantees a more accurate and efficient approach to cardiovascular therapy. The application of artificial intelligence has the potential to revolutionize drug delivery techniques. Large-scale datasets can be analyzed by AI-driven algorithms, which can then be used to predict the best quercetin formulations,

dosages, and delivery systems [82]. This method expedites clinical translation and simplifies the development process. Biomimetic delivery systems mimic the physiological processes of the body by taking inspiration from natural biological processes. By creating drug carriers that resemble physiological processes, quercetin's body compatibility is improved, which may lessen side effects and increase overall therapeutic efficacy [83].

9. Conclusion

This thorough investigation into quercetin-based drug delivery approaches for cardiovascular treatment reveals a promising field characterized by a variety of complex pharmacological characteristics and difficulties. The review highlights the vasodilatory, antioxidant, and anti-inflammatory properties of quercetin, establishing it as a promising therapeutic candidate. Innovative solutions are required to address challenges related to quercetin delivery, such as bioavailability constraints, targeted delivery issues, and safety concerns. Micelles, targeted ligand conjugation, and nanoparticle-based carriers have been identified as viable approaches to improve quercetin's effectiveness. Overcoming obstacles and guaranteeing effective clinical translation require collaborative strategies, such as interdisciplinary collaborations, industry-academia partnerships, and patient-centered research initiatives. Future advancements in biomimetic delivery systems, personalized medicine, advanced nanotechnology applications, and artificial intelligence integration hold the potential to transform quercetin-based drug delivery and usher in a new era of precision in cardiovascular therapy. Optimizing quercetin's therapeutic potential, resolving delivery issues, and encouraging cooperative strategies for success are implications for cardiovascular therapy. Future precision in cardiovascular therapy appears promising based on the predicted trends, as quercetin-based interventions can be customized to the unique characteristics of each patient, maximizing benefits and reducing side effects.

References

1. Azeem, M., et al., An insight into anticancer, antioxidant, antimicrobial, antidiabetic and anti-inflammatory effects of quercetin: A review. Polymer Bulletin, 2023. **80**(1): p. 241-262.
2. Luo, M., R. Tian, and N. Lu, Quercetin inhibited endothelial dysfunction and atherosclerosis in apolipoprotein E-deficient mice: critical roles for NADPH oxidase and heme oxygenase-1. Journal of Agricultural and Food Chemistry, 2020. **68**(39): p. 10875-10883.
3. Jantan, I., et al., Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways. The Journal of Nutritional Biochemistry, 2021. **93**: p. 108634.
4. Dagher, O., et al., Therapeutic potential of quercetin to alleviate endothelial dysfunction in age-related cardiovascular diseases. Frontiers in cardiovascular medicine, 2021. **8**: p. 220.
5. Deng, Q., et al., Therapeutic potential of quercetin as an antiatherosclerotic agent in atherosclerotic cardiovascular disease: a review. Evidence-Based Complementary and Alternative Medicine, 2020. **2020**.
6. Papakyriakopoulou, P., et al., Potential pharmaceutical applications of quercetin in cardiovascular diseases. Pharmaceuticals, 2022. **15**(8): p. 1019.
7. Joshi, A., et al., Systems biology in cardiovascular disease: a multiomics approach. Nature Reviews Cardiology, 2021. **18**(5): p. 313-330.
8. Vandenberghe, D. and J. Albrecht, The financial burden of non-communicable diseases in the European Union: a systematic review. European Journal of Public Health, 2020. **30**(4): p. 833-839.
9. Bucciarelli, V., et al., Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID syndrome: gender makes a difference. Trends in cardiovascular medicine, 2022. **32**(1): p. 12-17.
10. Mourad, O., et al., Modeling heart diseases on a chip: advantages and future opportunities. Circulation Research, 2023. **132**(4): p. 483-497.

11. Zakir, M., et al., Cardiovascular complications of diabetes: from microvascular to macrovascular pathways. Cureus, 2023. **15**(9).
12. Geremew, G., et al., Adherence to Lifestyle Modification Practices and Its Associated Factors Among Hypertensive Patients in Bahir Dar City Hospitals, North West Ethiopia. Integrated Blood Pressure Control, 2023: p. 111-122.
13. Hogervorst, S., et al., Scalability of effective adherence interventions for patients using cardiovascular disease medication: A realist synthesis-inspired systematic review. British journal of clinical pharmacology, 2023. **89**(7): p. 1996-2019.
14. Adhami, M., et al., Drug loaded implantable devices to treat cardiovascular disease. Expert Opinion on Drug Delivery, 2023. **20**(4): p. 507-522.
15. Pedretti, R.F., et al., How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology. European journal of preventive cardiology, 2023. **30**(2): p. 149-166.
16. Le, T.H., et al., Quercetin-incorporated collagen/chitosan/SiO2 composite toward the robust antioxidant biomaterials. International Journal of Polymeric Materials and Polymeric Biomaterials, 2023: p. 1-8.
17. Usman Abid, H.M., et al., Exploring the Potent Combination of Quercetin-Boronic Acid, Epalrestat, and Urea Containing Nanoethosomal Keratolytic Gel for the Treatment of Diabetic Neuropathic Pain: In Vitro and In Vivo Studies. Mol Pharm, 2023. **20**(7): p. 3623-3631.
18. Shabir, I., et al., Promising bioactive properties of quercetin for potential food applications and health benefits: A review. Frontiers in nutrition, 2022. **9**: p. 999752.
19. Nazari-Khanamiri, F. and M. Ghasemnejad-Berenji, Quercetin and Heart Health: From Molecular Pathways to Clinical Findings. Journal of Food Biochemistry, 2023. **2023**.
20. Pytliak, M. and V. Vaník, Quercetin as a Possible Cardiovascular Agent. 2023.
21. Azeem, M., et al., An insight into anticancer, antioxidant, antimicrobial, antidiabetic and anti-inflammatory effects of quercetin: a review. Polym Bull (Berl), 2023. **80**(1): p. 241-262.
22. Chiang, M.-C., T.-Y. Tsai, and C.-J. Wang, The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms. International Journal of Molecular Sciences, 2023. **24**(7): p. 6328.
23. Aghababaei, F. and M. Hadidi, Recent advances in potential health benefits of quercetin. Pharmaceuticals, 2023. **16**(7): p. 1020.
24. Zhou, Y., et al., Advance in the pharmacological effects of quercetin in modulating oxidative stress and inflammation related disorders. Phytotherapy Research, 2023. **37**(11): p. 4999-5016.
25. Azeem, M., et al., Enhanced antibacterial and antioxidant properties of chitosan-quercetin complex containing polycaprolactone microspheres for the treatment of gastroenteritis: An in-vitro and in-vivo analysis. Materials Today Communications, 2022. **31**: p. 103780.
26. Yamagata, K., Onion quercetin inhibits vascular endothelial cell dysfunction and prevents hypertension. European Food Research and Technology, 2023: p. 1-13.
27. Aatif, M., Current understanding of polyphenols to enhance bioavailability for better therapies. Biomedicines, 2023. **11**(7): p. 2078.
28. Alemzadeh, E., et al., Topical treatment of cutaneous leishmaniasis lesions using quercetin/Artemisia-capped silver nanoparticles ointment: Modulation of inflammatory response. Acta Tropica, 2022. **228**: p. 106325.
29. Mohamed, N.A., et al., Recent developments in nanomaterials-based drug delivery and upgrading treatment of cardiovascular diseases. International Journal of Molecular Sciences, 2022. **23**(3): p. 1404.
30. Mehboob, R., et al., Role of endothelial cells and angiotensin converting enzyme-II in COVID-19 and brain damages post-infection. Frontiers in Neurology, 2023. **14**.
31. Alajangi, H.K., et al., Blood–brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders. Molecular Brain, 2022. **15**(1): p. 1-28.

32. Wang, Y., et al., Development of innovative biomaterials and devices for the treatment of cardiovascular diseases. Advanced Materials, 2022. **34**(46): p. 2201971.
33. Dewanjee, S., et al., Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy. Drug Discovery Today, 2023. **28**(1): p. 103409.
34. Lohiya, G. and D.S. Katti, Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy. Carbohydrate Polymers, 2022. **277**: p. 118822.
35. Kaur, S., et al., Quercetin nanoformulations: recent advancements and therapeutic applications. Advances in Natural Sciences: Nanoscience and Nanotechnology, 2023. **14**(3): p. 033002.
36. Attar, E.S., et al., Nano Drug Delivery Strategies for an Oral Bioenhanced Quercetin Formulation. European Journal of Drug Metabolism and Pharmacokinetics, 2023. **48**(5): p. 495-514.
37. Črnivec, I.G.O., et al., Waste streams in onion production: bioactive compounds, quercetin and use of antimicrobial and antioxidative properties. Waste Management, 2021. **126**: p. 476-486.
38. Al-Khayri, J.M., et al., Flavonoids as potential anti-inflammatory molecules: A review. Molecules, 2022. **27**(9): p. 2901.
39. Hosseini, A., et al., Quercetin and metabolic syndrome: A review. Phytotherapy Research, 2021. **35**(10): p. 5352-5364.
40. Lin, X., et al., Quercetin improves vascular endothelial function through promotion of autophagy in hypertensive rats. Life Sciences, 2020. **258**: p. 118106.
41. Zhang, Y.-M., Z.-Y. Zhang, and R.-X. Wang, Protective mechanisms of quercetin against myocardial ischemia reperfusion injury. Frontiers in Physiology, 2020. **11**: p. 956.
42. Mirsafaei, L., et al., Molecular and biological functions of quercetin as a natural solution for cardiovascular disease prevention and treatment. Plant Foods for Human Nutrition, 2020. **75**: p. 307-315.
43. Alizadeh, S.R., N. Savadkouhi, and M.A. Ebrahimzadeh, Drug design strategies that aim to improve the low solubility and poor bioavailability conundrum in quercetin derivatives. Expert Opinion on Drug Discovery, 2023. **18**(10): p. 1117-1132.
44. Arshad, I., et al., Multifunctional role of nanoparticles for the diagnosis and therapeutics of cardiovascular diseases. Environmental Research, 2023: p. 117795.
45. Weisany, W., et al., Targeted delivery and controlled released of essential oils using nanoencapsulation: A review. Advances in Colloid and Interface Science, 2022. **303**: p. 102655.
46. Wadhwa, K., et al., New insights into quercetin nanoformulations for topical delivery. Phytomedicine Plus, 2022. **2**(2): p. 100257.
47. Hädrich, G., et al., Lipid-based nanocarrier for quercetin delivery: system characterization and molecular interactions studies. Drug Development and Industrial Pharmacy, 2016. **42**(7): p. 1165-1173.
48. Hanif, M., et al., Improved anti-inflammatory effect of curcumin by designing self-emulsifying drug delivery system. Drug Dev Ind Pharm, 2021. **47**(9): p. 1432-1438.
49. Gaspar, D.P., et al., Targeted delivery of lipid nanoparticles by means of surface chemical modification. Current Organic Chemistry, 2017. **21**(23): p. 2360-2375.
50. Nathiya, S., M. Durga, and D. Thiyagarajan, Quercetin, encapsulated quercetin and its application-a review. International Journal of Pharmacy and Pharmaceutical Sciences, 2014: p. 20-26.
51. Hoti, G., et al., Nutraceutical concepts and dextrin-based delivery systems. International Journal of Molecular Sciences, 2022. **23**(8): p. 4102.
52. Soumya, R.S. and K.G. Raghu, Recent advances on nanoparticle-based therapies for cardiovascular diseases. Journal of Cardiology, 2023. **81**(1): p. 10-18.
53. Rudrapal, M., et al., Nanodelivery of dietary polyphenols for therapeutic applications. Molecules, 2022. **27**(24): p. 8706.
54. Qi, X., et al., Development of quercetin-loaded PVCL–PVA–PEG micelles and application in inhibiting tumor angiogenesis through the PI3K/Akt/VEGF pathway. Toxicology and applied pharmacology, 2022. **437**: p. 115889.

55. Rathod, S., et al., Advances on nanoformulation approaches for delivering plant-derived antioxidants: A case of quercetin. International Journal of Pharmaceutics, 2022: p. 122093.
56. Lee, C.-S. and H.S. Hwang, Starch-Based Hydrogels as a Drug Delivery System in Biomedical Applications. Gels, 2023. **9**(12): p. 951.
57. Dhasmana, A., et al., A Bioengineered Quercetin-Loaded 3D Bio-Polymeric Graft for Tissue Regeneration and Repair. Biomedicines, 2022. **10**(12): p. 3157.
58. Rampin, A., et al., Recent advances in KEAP1/NRF2-targeting strategies by phytochemical antioxidants, nanoparticles, and biocompatible scaffolds for the treatment of diabetic cardiovascular complications. Antioxidants & Redox Signaling, 2022. **36**(10): p. 707-728.
59. Kaur, N., et al., Small molecules as cancer targeting ligands: Shifting the paradigm. Journal of Controlled Release, 2023. **355**: p. 417-433.
60. Dorostkar, H., et al., Reduction of Doxorubicin-Induced Cardiotoxicity by Co-Administration of Smart Liposomal Doxorubicin and Free Quercetin: In Vitro and In Vivo Studies. Pharmaceutics, 2023. **15**(7): p. 1920.
61. Singh, S., et al., Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders. Biochemical and Biophysical Research Communications, 2023.
62. Pechanova, O., E. Dayar, and M. Cebova, Therapeutic potential of polyphenols-loaded polymeric nanoparticles in cardiovascular system. Molecules, 2020. **25**(15): p. 3322.
63. Abid, S., et al., Unlocking the potential of phenyl boronic acid functionalized-quercetin nanoparticles: Advancing antibacterial efficacy and diabetic wound healing. Heliyon, 2024. **10**(1).
64. Ranjbar, S., et al., Lipid-Based Delivery Systems for Flavonoids and Flavonolignans: Liposomes, Nanoemulsions, and Solid Lipid Nanoparticles. Pharmaceutics, 2023. **15**(7): p. 1944.
65. Maity, S., A. Acharyya, and A.S. Chakraborti, Flavonoid-based polymeric nanoparticles: A promising approach for cancer and diabetes treatment. European Polymer Journal, 2022: p. 111455.
66. Kudaibergen, D., et al., Silica-Based Advanced Nanoparticles For Treating Ischemic Disease. Tissue Engineering and Regenerative Medicine, 2023. **20**(2): p. 177-198.
67. Gowthami, B., Harnessing Medicinal Plant Phytochemicals: Unveiling Pharmacological Potential and Novel Drug Delivery Strategies. International Journal of Research in Pharmaceutical Sciences and Technology, 2023. **4**(1): p. 11-17.
68. Hesari, M., et al., Current advances in the use of nanophytomedicine therapies for human cardiovascular diseases. International journal of nanomedicine, 2021: p. 3293-3315.
69. Mukherjee, P., et al., Role of animal models in biomedical research: a review. Laboratory Animal Research, 2022. **38**(1): p. 18.
70. Kozłowska, A. and D. Szostak-Węgierek, Targeting cardiovascular diseases by flavonols: An update. Nutrients, 2022. **14**(7): p. 1439.
71. Zhou, Y., et al., Roles and mechanisms of quercetin on cardiac arrhythmia: A review. Biomedicine & Pharmacotherapy, 2022. **153**: p. 113447.
72. Zhou, W., et al., Quercetin protects endothelial function from inflammation induced by localized disturbed flow by inhibiting NRP2-VEGFC complex. International Immunopharmacology, 2023. **116**: p. 109842.
73. Gui, Y., et al., Quercetin improves rapid endothelialization and inflammatory microenvironment in electrospun vascular grafts. Biomedical Materials, 2022. **17**(6): p. 065007.
74. Dadkhah Tehrani, S., et al., The effects of phytochemicals on serum triglycerides in subjects with hypertriglyceridemia: A systematic review of randomized controlled trials. Phytotherapy Research, 2023.
75. Luo, X., et al., A novel anti-atherosclerotic mechanism of quercetin: Competitive binding to KEAP1 via Arg483 to inhibit macrophage pyroptosis. Redox Biology, 2022. **57**: p. 102511.
76. McGuckin, M.B., et al., Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes. Journal of Controlled Release, 2022. **345**: p. 334-353.

77. Naik, G.G., et al., Phytopharmaceuticals and herbal drugs: prospects and safety issues in the delivery of natural products, in Phytopharmaceuticals and Herbal Drugs. 2023, Elsevier. p. 215-248.
78. Goswami, T. and A. Chaudhary, Synthesis of Curcumin-Quercetin Loaded Chitosan Nanoparticles for Antimicrobial and Anticancer Activity. 2023, Jaypee University of Information Technology, Solan, HP.
79. Mohammadiounotikandi, A., A Multidisciplinary approach to innovations in biomedical engineering for improved patient care and well-being. Archive of Biomedical Science and Engineering, 2023. **9**(1): p. 001-009.
80. Harish, V., et al., Cutting-edge advances in tailoring size, shape, and functionality of nanoparticles and nanostructures: A review. Journal of the Taiwan Institute of Chemical Engineers, 2023. **149**: p. 105010.
81. Xu, X., et al., Network pharmacology and experiment indicated that medicinal food homologous components play important roles in insomnia. Food Frontiers, 2023.
82. Alshawwa, S.Z., et al., Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics, 2022. **14**(4): p. 883.
83. Tang, P., et al., Challenges and opportunities for improving the druggability of natural product: Why need drug delivery system? Biomedicine & Pharmacotherapy, 2023. **164**: p. 114955.